

at rest and during exercise in COPD. *Thorax* 2005;**60**:916–24.

- 4 **Man WD**, Soliman MG, Gearing J, *et al.* Symptoms and quadriceps fatigability after walking and cycling in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2003;**168**:562–7.
- 5 **Punzal PA**, Ries AL, Kaplan RM, *et al.* Maximum intensity exercise training in patients with chronic obstructive pulmonary disease. *Chest* 1991;**100**:618–23.
- 6 **Mathur RS**, Revill SM, Vara DD, *et al.* Comparison of peak oxygen consumption during cycle and treadmill exercise in severe chronic obstructive pulmonary disease. *Thorax* 1995;**50**:829–33.
- 7 **Killian KJ**, Leblanc P, Martin DH, *et al.* Exercise capacity and ventilatory, circulatory, and symptom limitation in patients with chronic airflow limitation. *Am Rev Respir Dis* 1992;**146**:935–40.
- 8 **Pepin V**, Saey D, Whittom F, *et al.* Walking versus cycling: sensitivity to bronchodilation in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2005;**172**:1517–22.
- 9 **Lacasse Y**, Goldstein R, Lasserson TJ, *et al.* Pulmonary rehabilitation for chronic obstructive pulmonary disease. *Cochrane Database Syst Rev* 2006;(4):CD003793.
- 10 **Revill SM**, Morgan MD, Singh SJ, *et al.* The endurance shuttle walk: a new field test for the assessment of endurance capacity in chronic obstructive pulmonary disease. *Thorax* 1999;**54**:213–22.
- 11 **Liesker JJ**, Wijkstra PJ, ten Hacken NH, *et al.* A systematic review of the effects of bronchodilators on exercise capacity in patients with COPD. *Chest* 2002;**121**:597–608.
- 12 **O'Donnell DE**, Sciruba F, Celli B, *et al.* Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD. *Chest* 2006;**130**:647–56.
- 13 **O'Donnell DE**, Voduc N, Fitzpatrick M, *et al.* Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. *Eur Respir J* 2004;**24**:86–94.
- 14 **O'Donnell DE**, Fluge T, Gerken F, *et al.* Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. *Eur Respir J* 2004;**23**:832–40.
- 15 **Oga T**, Nishimura K, Tsukino M, *et al.* A comparison of the effects of salbutamol and ipratropium bromide on exercise endurance in patients with COPD. *Chest* 2003;**123**:1810–6.
- 16 **van't HA**, Gosselink R, Kwakkel G. Constant-load cycle endurance performance: test-retest reliability and validity in patients with COPD. *J Cardiopulm Rehabil* 2003;**23**:143–50.
- 17 **Sewell L**, Singh SJ, Williams JE, *et al.* Can individualized rehabilitation improve functional independence in elderly patients with COPD? *Chest* 2005;**128**:1194–200.
- 18 **Palange P**, Forte S, Onorati P, *et al.* Ventilatory and metabolic adaptations to walking and cycling in patients with COPD. *J Appl Physiol* 2000;**88**:1715–20.
- 19 **Oga T**, Nishimura K, Tsukino M, *et al.* The effects of oxitropium bromide on exercise performance in patients with stable chronic obstructive pulmonary disease. A comparison of three different exercise tests. *Am J Respir Crit Care Med* 2000;**161**:1897–901.
- 20 **Butland RJ**, Wang J, Gross ER, *et al.* Two-, six-, and 12-minute walking tests in respiratory disease. *BMJ (Clin Res Ed)* 1982;**284**:1607–8.
- 21 **Singh SJ**, Morgan MD, Scott S, *et al.* Development of a shuttle walking test of disability in patients with chronic airways obstruction. *Thorax* 1992;**47**:1019–24.
- 22 **Onorati P**, Antonucci R, Valli G, *et al.* Non-invasive evaluation of gas exchange during a shuttle walking test vs. a 6-min walking test to assess exercise tolerance in COPD patients. *Eur J Appl Physiol* 2003;**89**:331–6.
- 23 **Casaburi R**, Kukafka D, Cooper CB, *et al.* Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. *Chest* 2005;**127**:809–17.

Effect of steroids in asthma

Blanching the airways: steroid effects in asthma

Alan J Knox, Karl Deacon, Rachel Clifford

An important effect of steroids on angiogenesis in asthma

The vascular changes which occur in airways diseases such as asthma are starting to attract considerable attention from the respiratory research community. In addition to the vascular engorgement which occurs as part of the acute inflammatory process, several groups have demonstrated increased new vessel formation (angiogenesis) in chronic asthma.^{1–3} Not only does this occur in adult asthma, but recent studies suggest it is a prominent feature of childhood asthma, suggesting that vascular remodelling may occur relatively early in the asthmatic process.⁴ The increased airway wall thickening produced by the expanded vasculature causes enhanced airway narrowing on stimulation with constrictor agents, thereby contributing to bronchial hyper-responsiveness. Furthermore, the increased blood flow may increase inflammatory cell trafficking and exudation and transudation of cytokines and

mediators and contribute to airway hyper-responsiveness by supporting the increased airway smooth muscle mass which is a key feature of asthma histopathology.⁵ There are a number of candidate angiogenic factors for these changes, perhaps the most important of which are vascular endothelial growth factor (VEGF) and angiopoietin-1, distinct molecules which act together at different stages of angiogenic processes in several biological systems.^{6–15} Other molecules with angiogenic potential found in the airways include fibroblast growth factor,¹⁰ angiogenin¹⁰ and chemokines such as interleukin (IL)-8¹⁶ and eotaxin.¹⁷ VEGF is subject to dynamic regulation while angiopoietin-1 is less so, and the latter may contribute in a more permissive way to the remodelling process. A number of stimuli can increase VEGF release from lung cells including cigarette smoke, hypoxia and Th1 and Th2 cytokines such

as IL1 β , IL4 and IL13, remodelling cytokines such as TGF β and IL6, and vasoactive mediators such as bradykinin and PGE₂.^{18–27} Autocrine production of PGE₂ may mediate the effect of some of these agents,^{18, 27} and there is evidence from studies in mouse models to suggest that autocrine nitric oxide production may mediate some (but not all) of the effects of released VEGF in mouse asthma models.²⁸ Endogenous angiostatic molecules such as endostatin and angiopoietin-2 exert a brake on this process, and the dynamic interplay between these and pro-angiogenic molecules helps shape repair and remodelling.²⁹ Interestingly, recent studies in vitro with rhinovirus have shown that infection increases VEGF^{30, 31}—but not angiopoietin³⁰—release, suggesting a mechanism whereby recurrent viral airway infections might contribute to airway remodelling in a cyclical manner. In mouse asthma models, airway VEGF is increased and VEGF receptor inhibitors inhibit cellular influx as well as inhibiting airway hyper-responsiveness and reducing microvascular leakage,³² consistent with VEGF having an important deleterious effect in asthma. In these and other studies,¹⁵ VEGF appears to regulate inflammatory processes as well as remodelling, which suggests that it is a complex multifunctional molecule with a wide repertoire of effects. There also appears to be a close relation between VEGF and matrix degradation which probably reflects the fact that establishment of

new vessels requires matrix turnover and that, when the matrix is damaged, new vessels are required for tissue repair.

The study in this issue of *Thorax* by Feltis and colleagues³³ (see page 314) addresses an important issue—namely, whether these angiogenic processes are modified by glucocorticoids. The authors undertook a placebo-controlled intervention study with inhaled fluticasone in 35 patients with mild asthma and performed immunohistochemistry and image analysis to obtain quantitative measures of vessels, angiogenic sprouts, VEGF, VEGF receptor 1, VEGF receptor 2 and angiotensin-1 staining in airway biopsy specimens. They also measured VEGF concentrations in lavage fluid. The key findings were that vessel number, VEGF and sprout staining were decreased after 3 months of inhaled steroid treatment. However, no further reduction was seen at 12 months and relatively high doses of fluticasone were required. Their findings suggest that inhaled steroids downregulate angiogenic remodelling in the airways in asthma, associated with decreasing VEGF activity within the airway wall. Interestingly, VEGF levels in lavage fluid were not altered nor were receptor numbers or staining for angiotensin-1. An interesting finding in this study was the fact that the vascular “sprouts”, which these authors have reported previously,³⁴ were also reduced by fluticasone treatment. It would seem likely that these cystic structures in the vascular wall of airway vessels may be newly forming vessels.

Glucocorticoids have also been shown to reduce VEGF release in airway cell systems in culture, although their precise mechanism of action has not been established.³⁵ VEGF regulation is complex and is controlled at both transcriptional and translational levels. Transcription factor binding sites in the VEGF promoter for specificity protein-1 (SP-1) seem to be particularly important, at least in airway smooth muscle,²⁶ although this has not been studied in other airway cells. VEGF mRNA has regulatory elements in both its 3' and 5' UTR which control its degradation and are potential sites for post-transcriptional regulation.³⁶ It is not clear whether the effect of glucocorticoids on VEGF production and angiogenesis is mediated by an effect on transcriptional or translational processes.

If glucocorticoids inhibit bronchial vascular changes, what is known about other asthma treatments? Interestingly, long-acting β -agonists have been shown to reduce the vascularity of asthmatic airways in vivo.¹ Although there is some evidence that it might be due to a reduction in VEGF,³⁵ an alternative explanation

might be a reduction in the level of pro-angiogenic chemokines such as IL8³⁷ and eotaxin.³⁸ The leucotriene antagonist pranlukast reduced sputum VEGF levels in a small study of untreated asthmatic subjects but had no additional effect when given concomitantly with inhaled steroids.³⁹

Most studies on bronchial angiogenesis to date have used cell culture systems with relevant airway cells in vitro or biopsy studies such as those of Feltis *et al.*³³ Recent reports of new three-dimensional cell culture systems for studying angiogenesis in vitro⁴⁰ and reports using magnetic resonance imaging in animal models in vivo⁴¹ might provide additional tools, allowing a greater understanding of this important process over the next few years.

Thorax 2007;**62**:283–285.
doi: 10.1136/thx.2006.073221

Authors' affiliations

Alan J Knox, Karl Deacon, Rachel Clifford, Division of Respiratory Medicine, Centre for Respiratory Research, Clinical Sciences Building, Nottingham City Hospital, Nottingham, UK

Correspondence to: Professor A J Knox, Division of Respiratory Medicine, Centre for Respiratory Research, Clinical Sciences Building, Nottingham City Hospital, Hucknall Road, Nottingham NG5 1PB, UK; alan.knox@nottingham.ac.uk

Competing interests: None.

REFERENCES

- Orsida BE, Ward C, Li X, *et al.* Effect of a long-acting beta₂-agonist over three months on airway wall vascular remodeling in asthma. *Am J Respir Crit Care Med* 2001;**164**:117–21.
- Orsida BE, Li X, Hickey B, *et al.* Vascularity in asthmatic airways: relation to inhaled steroid dose. *Thorax* 1999;**54**:289–95.
- Salvato G. Quantitative and morphological analysis of the vascular bed in bronchial biopsy specimens from asthmatic and non-asthmatic subjects. *Thorax* 2001;**56**:902–6.
- Barbato A, Turato G, Baraldo S, *et al.* Epithelial damage and angiogenesis in the airways of children with asthma. *Am J Respir Crit Care Med* 2006;**174**:975–81.
- Knox AJ, Stocks J, Sutcliffe A. Angiogenesis and vascular endothelial growth factor in COPD. *Thorax* 2005;**60**:88–9.
- Asai K, Kanazawa H, Kamoi H, *et al.* Increased levels of vascular endothelial growth factor in induced sputum in asthmatic patients. *Clin Exp Allergy* 2003;**33**:595–9.
- Kanazawa H, Hirata K, Yoshikawa J. Involvement of vascular endothelial growth factor in exercise induced bronchoconstriction in asthmatic patients. *Thorax* 2002;**57**:885–8.
- McDonald DM. Angiogenesis and remodeling of airway vasculature in chronic inflammation. *Am J Respir Crit Care Med* 2001;**164**:S39–45.
- Hoshino M, Nakamura Y, Hamid QA. Gene expression of vascular endothelial growth factor and its receptors and angiogenesis in bronchial asthma. *J Allergy Clin Immunol* 2001;**107**:1034–8.
- Hoshino M, Takahashi M, Aoike N. Expression of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin immunoreactivity in asthmatic airways and its relationship to angiogenesis. *J Allergy Clin Immunol* 2001;**107**:295–301.

- Yancopoulos GD, Davis S, Gale NW, *et al.* Vascular-specific growth factors and blood vessel formation. *Nature* 2000;**407**:242–8.
- Ribatti D, Vacca A, Presta M. The discovery of angiogenic factors: a historical review. *Gen Pharmacol* 2000;**35**:227–31.
- Baluk P, Lee CG, Link H, *et al.* Regulated angiogenesis and vascular regression in mice overexpressing vascular endothelial growth factor in airways. *Am J Pathol* 2004;**165**:1071–85.
- Rothenberg ME. VEGF obstructs the lungs. *Nat Med* 2004;**10**:1041–2.
- Lee CG, Link H, Baluk P, *et al.* Vascular endothelial growth factor (VEGF) induces remodeling and enhances TH2-mediated sensitization and inflammation in the lung. *Nat Med* 2004;**10**:1095–103.
- Tanner JE. Nucleosomes activate NF-kappaB in endothelial cells for induction of the proangiogenic cytokine IL-8. *Int J Cancer* 2004;**112**:155–60.
- Salcedo R, Young HA, Ponce ML, *et al.* Eotaxin (CCL11) induces in vivo angiogenic responses by human CCR3+ endothelial cells. *J Immunol* 2001;**166**:7571–8.
- Knox AJ, Corbett L, Stocks J, *et al.* Human airway smooth muscle cells secrete vascular endothelial growth factor: up-regulation by bradykinin via a protein kinase C and prostanoicid-dependent mechanism. *FASEB J* 2001;**15**:2480–8.
- Wright JL, Tai H, Churg A. Cigarette smoke induces persisting increases of vasoactive mediators in pulmonary arteries. *Am J Respir Cell Mol Biol* 2004;**31**:501–9.
- Nilsson I, Shibuya M, Wennstrom S. Differential activation of vascular genes by hypoxia in primary endothelial cells. *Exp Cell Res* 2004;**299**:476–85.
- Wen FQ, Liu X, Manda W, *et al.* TH2 Cytokine-enhanced and TGF-beta-enhanced vascular endothelial growth factor production by cultured human airway smooth muscle cells is attenuated by IFN-gamma and corticosteroids. *J Allergy Clin Immunol* 2003;**111**:1307–18.
- Ammit AJ, Moir LM, Oliver B, *et al.* Effect of IL-6 trans-signaling on the pro-remodeling phenotype of airway smooth muscle. *Am J Physiol Lung Cell Mol Physiol* 2007;**292**:L199–206.
- Alagappan VK, McKay S, Widyastuti A, *et al.* Proinflammatory cytokines upregulate mRNA expression and secretion of vascular endothelial growth factor in cultured human airway smooth muscle cells. *Cell Biochem Biophys* 2005;**43**:119–29.
- Faffe DS, Flynt L, Bourgeois K, *et al.* Interleukin-13 and interleukin-4 induce vascular endothelial growth factor release from airway smooth muscle cells: role of vascular endothelial growth factor genotype. *Am J Respir Cell Mol Biol* 2006;**34**:213–8.
- Faffe DS, Flynt L, Mellema M, *et al.* Oncostatin M causes VEGF release from human airway smooth muscle: synergy with IL-1beta. *Am J Physiol Lung Cell Mol Physiol* 2005;**288**:L1040–8.
- Bradbury D, Clarke D, Seedhouse C, *et al.* Vascular endothelial growth factor induction by prostaglandin E2 in human airway smooth muscle cells is mediated by E prostanoicid EP2/EP4 receptors and SP-1 transcription factor binding sites. *J Biol Chem* 2005;**280**:29993–30000.
- Stocks J, Bradbury D, Corbett L, *et al.* Cytokines upregulate vascular endothelial growth factor secretion by human airway smooth muscle cells: role of endogenous prostanoicids. *FEBS Lett* 2005;**579**:2551–6.
- Bhandari V, Choo-Wing R, Chapoval SP, *et al.* Essential role of nitric oxide in VEGF-induced, asthma-like angiogenesis, inflammatory, mucus, and physiologic responses in the lung. *Proc Natl Acad Sci USA* 2006;**103**:11021–6.
- Suzaki Y, Hamada K, Sho M, *et al.* A potent antiangiogenic factor, endostatin prevents the development of asthma in a murine model. *J Allergy Clin Immunol* 2005;**116**:1220–7.
- Psarras S, Volonaki E, Skevaki CL, *et al.* Vascular endothelial growth factor-mediated induction of angiogenesis by human rhinoviruses. *J Allergy Clin Immunol* 2006;**117**:291–7.
- De Silva D, Dagher H, Ghildyal R, *et al.* Vascular endothelial growth factor induction by rhinovirus infection. *J Med Virol* 2006;**78**:666–72.

32 Lee YC, Kwak YG, Song CH. Contribution of vascular endothelial growth factor to airway hyperresponsiveness and inflammation in a murine model of toluene diisocyanate-induced asthma. *J Immunol* 2002;**168**:3595–600.

33 Feltis BN, Wignarajah D, Reid DW, *et al*. Effects of inhaled fluticasone on angiogenesis and vascular endothelial growth factor in asthma. *Thorax* 2007;**62**:314–9.

34 Feltis BN, Wignarajah D, Zheng L, *et al*. Increased vascular endothelial growth factor and receptors: relationship to angiogenesis in asthma. *Am J Respir Crit Care Med* 2006;**173**:1201–7.

35 Volonaki E, Psarras S, Xepapadaki P, *et al*. Synergistic effects of fluticasone propionate and salmeterol on inhibiting rhinovirus-induced epithelial production of remodeling-associated growth factors. *Clin Exp Allergy* 2006;**36**:1268–73.

36 Yoo PS, Mulkeen AL, Cha CH. Post-transcriptional regulation of vascular endothelial growth factor: implications for tumor angiogenesis. *World J Gastroenterol* 2006;**12**:4937–42.

37 Nie M, Knox AJ, Pang L. β_2 -Adrenoceptor agonists, like glucocorticoids, repress eotaxin gene transcription by selective inhibition of histone H4 acetylation. *J Immunol* 2005;**175**:478–86.

38 Pang L, Knox AJ. Synergistic inhibition by beta(2)-agonists and corticosteroids on tumor necrosis factor-alpha-induced interleukin-8 release from cultured human airway smooth-muscle cells. *Am J Respir Cell Mol Biol* 2000;**23**:79–85.

39 Kanazawa H, Yoshikawa T, Hirata K, *et al*. Effects of pranlukast administration on vascular endothelial growth factor levels in asthmatic patients. *Chest* 2004;**125**:1700–5.

40 Thompson HG, Truong DT, Griffith CK, *et al*. A three-dimensional in vitro model of angiogenesis in the airway mucosa. *Pulm Pharmacol Ther* 2007;**20**:141–8.

41 Tigani B, Cannet C, Quintana HK, *et al*. Lung inflammation and vascular remodeling after repeated allergen challenge detected noninvasively by MRI. *Am J Physiol Lung Cell Mol Physiol*, 2006 [Epub ahead of print].

Bimodality surveillance of high-risk patients for lung cancer

Bimodality surveillance of high-risk patients for lung cancer

Gordon H Downie

Are new diagnostic strategies providing answers?

Thoracic oncology providers confronted with the task of diagnosing and following patients at risk for cancer of the lung face a number of major dilemmas, some of which directly affect the ability to diagnose. First, the majority of patients with lung cancer are diagnosed at a late stage and <15% survive 5 years, so a degree of nihilism is present in patients, providers and policy makers. Second, risk paradigms are changing, from smoking only to occupational, environmental or home carcinogens to the risk associated with premalignant airway changes. Third, advances in early diagnostic options have the potential to discover lung carcinoma while still in a pre-invasive, minimally invasive stage or as small peripheral nodules. These points, taken in conjunction with the initial clinical results of the ELCAP study suggesting that cure is possible,¹ raise the need to examine early diagnostic strategies critically.

In this issue of *Thorax* (see page 335) Loewen *et al* report their initial clinical findings in bimodality surveillance of high risk for lung cancer populations using low dose spiral CT scanning (SCT) and autofluorescence bronchoscopy (AFB).² They examined two null hypotheses: (1) AFB was equivalent to conventional sputum cytology (CSC) for the detection of pre-malignant lesions and (2) AFB and SCT would be equivalent to SCT alone for the detection of lung cancer

in high-risk patients. The authors conclude that AFB is significantly superior to CSC for the detection of airway pre-malignancy in this cohort of high-risk patients and, in fact, argue that, as a surveillance tool, AFB exceeds the cancer detection rate of colonoscopy in patients with positive fecal occult blood. However, the authors were not able to demonstrate a significant superiority of bimodality surveillance with both AFB and SCT over SCT alone, but question whether a larger sample size would have found bimodality significantly better.

Beyond their null hypotheses, the article raises several points that are healthy components of any discussion of the future approach to patients at high risk of lung cancer. These include:

1. Premalignant changes are common (66% of the 169 patients receiving all components of surveillance) in this high-risk cohort.
2. AFB is reasonable in patients with atypia in CSC; however, CSC was inadequate for detection of pre-malignant cytology when frank carcinoma was not present.
3. Screening and surveillance are very different and surveillance of a select population may be a superior strategy in lung cancer management.
4. Regardless of the histology of the lung cancers detected in this study (>50% were adenocarcinoma), the

- majority of patients had central airway pre-malignant transformation.
5. Spiral CT scan protocols are not adequate at this time for detecting central airway disease by themselves.
 6. Central airway pre-malignant lesions appear to be predictive of the presence of peripheral adenocarcinoma identified by SCT.

Several of these observations or conclusions have not been supported by other articles in the field. Haubinger *et al*³ performed a prospective, randomised, multicentre trial comparing white light bronchoscopy (WLB) with or without AFB. The high-risk group defined by chronic obstructive pulmonary disease plus occupational exposure failed to demonstrate severe dysplasia or carcinoma-in-situ (CIS), although it was unclear to what extent metaplasia or mild dysplasia were seen in this cohort. Swensen *et al*⁴ and Bechtel *et al*⁵ in two separate studies used bimodality testing using CSC as one portion of their testing and suggested a more significant contribution for CSC in lung cancer detection than was suggested by Loewen *et al*.² However, because of different study designs including inclusion criteria, biopsy and statistical methods and pathology review variations,⁶ it may be nearly impossible to compare findings from one study to another.

Although Loewen *et al* raise several compelling clinical questions in their paper, the most pivotal may well be management issues of airway cellular transformation including dysplasia and CIS. The diagnosis, progression and treatment of dysplasia and CIS, especially in high-risk populations, are demanding more clinical attention to determine surveillance strategies and may affect overall outcomes of lung cancer in the near future. Intense interest in this topic was indicated when most sessions at the 11th World Congress on Lung Cancer in